Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer
Status:
Terminated
Trial end date:
2019-06-19
Target enrollment:
Participant gender:
Summary
Patient with Non-Small Cell Lung Cancer (NSCLC) that might have a genetic change (mutation)
in the Epidermal Growth Factor Receptor (EGFR) are invited to take part in this study.
This research study is evaluating a new blood test that is capable of detecting an EGFR
mutation in cancer without a biopsy.